Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics to Continue Cancer Biomarker Collaboration with AstraZeneca

NEW YORK, May 16 (GenomeWeb News) - Epigenomics said today that it will continue a collaboration with AstraZeneca to identify DNA methylation biomarker candidates for use in AstraZeneca's oncology programs.


Epigenomics said that it successfully completed a biomarker-discovery study with AstraZeneca last year, and that it will now test the potential of those markers to predict response to EGFR inhibitors such as AstraZeneca's Iressa in a panel of preclinical cancer models.


Under the terms of the agreement, Epigenomics will receive R&D fees and can participate in the development of any pharmacodiagnostic products resulting from the collaboration.


Further financial details were not disclosed.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.